Search
for
Sort by
Research 121–150 of 1000+
- Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
- Interleukin-6 Null Mice Paradoxically Display Increased STAT3 Activity and Wound-Induced Hair Neogenesis
- Efficacy and Potential Mechanisms of Naringin in Atopic Dermatitis
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- A new era for alopecia areata: New treatments and improved knowledge of the condition
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- One of the best treatments for alopecia areata remains unpublished
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- Myeloproliferative disorder associated with alopecia universalis
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Skin Biology and Ageing
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- IN-SILICO STUDY OF BIOACTIVE COMPOUNDS OF NATURAL MATERIALS AS A JAK- SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION INHIBITOR FOR ANTI-ALOPECIA
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- Hair-Growth Potential of Ginseng and Its Major Metabolites: A Review on Its Molecular Mechanisms
- Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib
- 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
- 0975 Single-cell transcriptomic profiling reveals distinct immunopathogenic programs in alopecia totalis/universalis compared to patchy alopecia areata
- Spotlight in Plastic Surgery: October 2022
- Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Ruxolitinib: A novel molecule in the management of dermatological disorders
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials